Changes to the Pharmaceutical Benefits Advisory Committee

D. Henry,D. Birkett
DOI: https://doi.org/10.5694/J.1326-5377.2001.TB143234.X
2001-03-01
Abstract:. .• advisory bodies such as the PBAC need the strong and unambiguous support of government. and a guarantee of Independence , 0 :-: 31 DF.CE...1BER 2000,th e Pharmaceutical Benefits AdviWf" Committee (PBnG) an d its Economics andDrug C'tiliSJlj,)n subcommitteeswere dissolved under legislation ー 。 セ B エ G 、 precipitately through the Federal Senate . POAe mCl':1bcrs, the media and some politicians were surp rised by tlus legislativehastc; '·l suc h urgency and resolveappeared inw ngruQus for legislation of an appar ently rout inenature. A review gro up (including PBAC represen t anvcs), convened by the Parliamentary Secretary (or Health 10 review aspects of theCommittee's operations, had rec ommended th.\! PBAC members sho uld come from abroader range of eonnnueacles, and that membership tenureshouldbe limil(\ l "fo ensure the cont inued effectiveness of the Co mmitlee, they also re commended a transuional pha se for implementing thechanges.Thus, the legislativeamendment
What problem does this paper attempt to address?